Key Highlights
- Serina Therapeutics shares rocketed 39.45% in extended trading to $1.78 from a regular close of $1.28.
- A $15 million initial private placement is set to close March 20, with another $15 million tranche available by April 30.
- Full warrant exercise could generate an additional $33.3 million, potentially funding operations through H2 2027.
- Shares are priced at $2.25 — representing a 68% premium over the March 17 close.
- Greg Bailey, a board member with ties to Pfizer’s $11.6B Biohaven and $14B Medivation acquisitions, will assume Co-Chairman duties.
Serina Therapeutics (SER) experienced a dramatic after-hours rally Wednesday, climbing nearly 40% following the biotech firm’s disclosure of a private placement that could generate as much as $63.3 million.
Serina Therapeutics, Inc., SER
The sharp move higher occurred in extended trading after Serina disclosed that an initial $15 million tranche is slated to close March 20, 2026. An additional tranche of up to $15 million could close by April 30.
Shares traded at $1.78 after-hours, a substantial gain from the regular session’s $1.28 close — which itself was down 4.48% during standard trading hours.
The financing sets the share price at $2.25, marking a 68% premium relative to where the stock closed on March 17. Each share or pre-funded warrant includes a half-warrant exercisable at $5.00 per share. With a four-year duration, full exercise of these warrants could contribute another $33.3 million, bringing the aggregate potential proceeds to $63.3 million.
For a clinical-stage biotech, that capital injection is significant. Serina projects the funding will sustain operations into the second half of 2027.
Veteran Biotech Investor Steps Into Leadership
The financing round is being spearheaded by Greg Bailey, M.D., an existing board member who will transition into the role of Co-Chairman alongside current chair Simba Gill, Ph.D.
Bailey’s resume carries weight in biotech circles. He was an early investor in Biohaven Ltd., which Pfizer acquired in 2022 for roughly $11.6 billion, as well as Medivation, purchased by Pfizer in 2016 for $14 billion.
That background resonated with the market. When a seasoned investor with exits of that magnitude leads a financing, it tends to signal confidence to other shareholders.
Capital Allocation: Advancing the Parkinson’s Pipeline
The raised funds will primarily support Serina’s SER-252 registrational study, a Phase 1b trial focused on advanced Parkinson’s disease. Patient enrollment is underway at clinical sites in Australia and the United States.
SER-252 is being pursued through the FDA’s 505(b)(2) pathway, a route CEO Steve Ledger characterized as “capital-efficient.” Dosing of the first participant has already occurred.
The company anticipates that safety data from Cohort 1 will enable progression to Cohort 2 during Q3 2026. Topline data from the single-ascending dose portion of the trial are expected in the first half of 2027.
The therapy is aimed at roughly 250,000 patients with advanced Parkinson’s disease across the U.S. and Europe whose conditions are not sufficiently managed by existing therapies.
Despite Wednesday’s after-hours surge, the stock’s broader trajectory remains challenged. SER has a 52-week trading range between $1.22 and $7.92 and has fallen 71.11% over the trailing 12 months. The company’s market capitalization currently sits at just $13.65 million, and its RSI reading of 29.86 indicates deeply oversold conditions.
SER ended Wednesday’s regular trading session at $1.28, down 4.48% for the day.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
